secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2026-07-18T00:41:06+00:00
Accession:  0001104659-26-084760
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

VYNE stockholders approve all proposals for merger with Yarrow Bioscience at special meeting
--------------------------------------------------------------------------------

- Proposal 1 (issuance of shares >20% and change of control) approved: 15,915,017 for, 137,159 against.
- Proposal 2 (reverse stock split 1:10-70) approved: 25,389,760 for, 550,694 against.
- Proposal 3 (increase authorized shares from 150M to 300M) approved: 23,921,348 for, 2,013,526 against.
- Proposal 4 (Yarrow 2026 Stock Incentive Plan) approved: 12,691,384 for, 3,358,164 against.
- Proposal 5 (Yarrow 2026 Employee Stock Purchase Plan) approved: 13,131,018 for, 2,909,493 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465926084760/0001104659-26-084760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465926084760/tm2620687d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-084760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer